[Specific treatment attempt, with ticlopidine, of patients with Chagas disease chronic phase].
In a previous study, ticlopidine decreased the parasitemia and mortality of mice infected by Trypanosoma cruzi. Therefore, this drug was administered to 12 patients with Chagas' disease, in the chronic phase. For 90 days, 150, 200 or 250 mg were utilized according to whether the recipients were children, adolescents or adults, respectively. A fully unsuccessful outcome was documented, both serologically as well as parasitologically.
Rassi
A
A
Hospital São Salvador, Goiânia, GO, Brasil.
Amato Neto
V
V
Rassi
G G
GG
Ferriolli Filho
F
F
Amato
V S
VS
D000293:Adolescent; D000328:Adult; D014355:Chagas Disease / Q000188:drug therapy*; D002648:Child; D002908:Chronic Disease; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D013988:Ticlopidine / Q000627:therapeutic use*; D017211:Treatment Failure; D014344:Trypanocidal Agents / Q000627:therapeutic use*
D014344:Trypanocidal Agents; D013988:Ticlopidine